Impact of COVID-19 on Drug Development in Rare Disease and Oncology
The full effect of the COVID-19 pandemic, particularly on the search for rare disease and oncology treatments, is still uncertain. What we do know is that patients diagnosed with these conditions simply cannot afford delays. With a patient-centric approach and guided by the best minds in the industry, Parexel has a broad perspective to help sponsors, regulators, and patients during this difficult time. We have learned a great deal over the past few months about trial conduct, patient recruitment, risk mitigation, the pace of regulatory approvals, and how patients are faring. And now we want to share this information with you.
Related Insights
Blog
Celebrating 40 Years of Rare Disease Progress: WODC Highlights
Jun 6, 2023
Blog
Studying rare cancer patient populations using integrated genomic and real-world data
Aug 30, 2023
Report
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023
Blog
Parexel names first Patient Ambassador
Jun 17, 2022
Blog
Patient-guided oncology trials: Why the patient perspective is essential to success
Jun 4, 2024
Webinar
FDA Rare Disease Innovation Hub: Enhancing Collaboration and Speed?
Jan 7, 2025
Article
Five strategies for meeting the requirements of Project Optimus and improving the chances of approval
Nov 10, 2022
Article
Q&A Project Optimus: What you need to know
Oct 11, 2022
Webinar
Challenges and best practices for developing Antibody-Drug Conjugates (ADCs)
Nov 12, 2024
Webinar
Navigating the complexities of AML drug development
Oct 30, 2024
Blog
Adapting the validation process for PROs for rare diseases and other diseases with large unmet need and/or rapid progression
Apr 23, 2024
Blog
PD-1 inhibitors face scrutiny in esophageal cancer: Key takeaways for drug developers
Oct 4, 2024
Related Insights
Blog
Celebrating 40 Years of Rare Disease Progress: WODC Highlights
Jun 6, 2023
Blog
Studying rare cancer patient populations using integrated genomic and real-world data
Aug 30, 2023
Report
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023
Blog
Parexel names first Patient Ambassador
Jun 17, 2022
Blog
Patient-guided oncology trials: Why the patient perspective is essential to success
Jun 4, 2024
Webinar
FDA Rare Disease Innovation Hub: Enhancing Collaboration and Speed?
Jan 7, 2025
Article
Five strategies for meeting the requirements of Project Optimus and improving the chances of approval
Nov 10, 2022
Article
Q&A Project Optimus: What you need to know
Oct 11, 2022
Webinar
Challenges and best practices for developing Antibody-Drug Conjugates (ADCs)
Nov 12, 2024
Webinar
Navigating the complexities of AML drug development
Oct 30, 2024
Blog
Adapting the validation process for PROs for rare diseases and other diseases with large unmet need and/or rapid progression
Apr 23, 2024
Blog
PD-1 inhibitors face scrutiny in esophageal cancer: Key takeaways for drug developers
Oct 4, 2024